Checkpoint Inhibition in Stage III NSCLC: Current Practice, Open Questions, and Future Directions

Designed to improve clinician performance and patient outcomes, this interactive symposium will investigate the subtleties and challenges of optimal clinical application of checkpoint inhibition for treating unresectable stage III NSCLC. Gain expert insights on when and how to use immune checkpoint inhibitors in this earlier disease setting, with an opportunity to submit your most pressing questions.

Reserve your spot now!

The "Checkpoint Inhibition in Stage III NSCLC: Current Practice, Open Questions, and Future Directions,” content and views expressed therein are those of Clinical Care Options, LLC and not of SITC.

Agenda

12:45 PM - 1:00 PM: Lunch and Registration

1:00 PM - 1:05 PM: Welcome and Introduction

1:05 PM - 1:20 PM: Current Practice: Checkpoint Inhibitors in Unresectable Stage III NSCLC Edward B. Garon, MD, MS

1:20 PM - 1:45 PM: Open Questions: Case Discussions on Optimal Integration of Checkpoint Inhibitors into the Management of Unresectable Stage III NSCLCJulie Brahmer, MD, MSc

1:45 PM - 1:55 PM: Future Directions: Moving Checkpoint Inhibitors into Earlier NSCLC Settings Naiyer Rizvi, MD

1:55 PM - 2:00 PM: Final Panel Discussion and Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Julie Brahmer, MD

Professor of Oncology
Director, 
Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Faculty
Edward Garon, MD

Associate Clinical Professor
Director,
Thoracic Oncology Program
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Faculty
Naiyer Rizvi, MD

Price Family Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy
Columbia University Medical Center
New York, New York

CME

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians to integrate immune checkpoint inhibitors into treatment of their patients with stage III non-small-cell lung cancer.

Target Audience 
This program is intended for physicians and other healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives 

  • Discuss the biologic rationale for using immune checkpoint inhibitors in patients with locally advanced NSCLC
  • Plan optimal, individualized therapeutic strategies for patients with stage III NSCLC, considering the available clinical evidence, expert recommendations, and patient preferences
  • Identify subsets of patients with stage III NSCLC in which current research is conclusive, suggestive, or not available for benefit from durvalumab consolidation after definitive platinum-based chemotherapy and concurrent radiation therapy
  • Describe ways that the use of immunotherapy in earlier stages of disease may require a different understanding of risk/benefit and applicable subsets of patients

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.